The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy. Leukemia & lymphoma [Leuk Lymphoma] Journal article

Title	The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy.
Author(s)	D'adda M, Micheletti M, Drera M, Ferrari S, Rossi G
Institution	Department of Medical Oncology, Hematology Division, Spedali Civili, Brescia, Italy.
Source	Leuk Lymphoma 2008 Nov; 49(11):2216-2218.
Language	ENG
Pub Type(s)	LETTER
PubMed ID	19021067

Advertise on this site.